2019
DOI: 10.31557/apjcp.2019.20.1.263
|View full text |Cite
|
Sign up to set email alerts
|

Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells

Abstract: new antitumor drugs, operation, intervene therapy, liver transplantation (LT), and so on. Liver resection is still the mainstay of treatment for HCC and provides the consistent long-term survival. However, the resectability is limited by tumor extent, location, or underlying liver dysfunction, with only a minority of HCC being potentially resectable. All these leave LT rather than liver resection as the only potentially curative option, which increase the possibilities of HCC resection for patients with nonres… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 29 publications
0
8
0
Order By: Relevance
“…Meaningfully, the synergistic effect of sorafenib and 80% MSCs-CM in HCC cells is of clinical significance, allowing the use of lower doses of sorafenib and being more effective than currently single use. 33 More precise drug-resistant targets have already arisen. For example, GRP78, overexpressed in sorafenib-resistant liver cancer cells, is used as a therapeutic target of siGRP78-modified MSCs exosomes combined with sorafenib in HCC cells, thereby weakening the growth and invasion of cancer cells in vivo and in vitro, reversing sorafenib resistance.…”
Section: Mscs and Sorafenibmentioning
confidence: 99%
“…Meaningfully, the synergistic effect of sorafenib and 80% MSCs-CM in HCC cells is of clinical significance, allowing the use of lower doses of sorafenib and being more effective than currently single use. 33 More precise drug-resistant targets have already arisen. For example, GRP78, overexpressed in sorafenib-resistant liver cancer cells, is used as a therapeutic target of siGRP78-modified MSCs exosomes combined with sorafenib in HCC cells, thereby weakening the growth and invasion of cancer cells in vivo and in vitro, reversing sorafenib resistance.…”
Section: Mscs and Sorafenibmentioning
confidence: 99%
“…The MSCs secrete a number of paracrine factors, cytokines, and vascular endothelial growth factor (VEGF), which may influence the proliferation and viability of cancer cells. In this regard, MSCs secretome may affect tumor cells and inhibit their development (19). The hWJSCs have been used as an anticancer agent in many previous studies (20,21).…”
Section: Discussionmentioning
confidence: 99%
“…Seyhoun et al were able to demonstrate that co-treatment with sorafenib alongside MSC CM was able to enhance the cytotoxic effects of sorafenib on HepG2 cell lines [ 169 ]. The combination of sorafenib with MSCs showed a similar result, which included the inhibition of hepatocellular carcinoma growth in a mouse model [ 170 ].…”
Section: Antitumor Properties Of Mesenchymal Stromal Cell Derived Ext...mentioning
confidence: 99%